Font Size: a A A
Keyword [Immune Checkpoint]
Result: 181 - 200 | Page: 10 of 10
181. Evaluating The Value Of Tumor Immune Precision Medical Based On Tumor Mutation Burden Detection
182. Meta-analysis Of Related Adverse Events Caused By ICIs Alone Or Combined With Routine Chemotherapy In The Treatment Of NSCLC
183. Meta-analysis Of The Correlation Between Immune-related Adverse Events And Efficacy Of Immune Checkpoint Inhibitors In The Treatment Of Non-small Cell Lung Cancer
184. Meta-analysis Of Effects Of Glucocorticoids On Immune Checkpoint Inhibitors In The Treatment Of Malignancies
185. Effects Of Antibacterials On The Immunotherapy Of NSCLC:A Meta-analysis
186. Immune Checkpoint Blockade Immunotherapy Combined With Integrin αvβ3-targeted Radionuclide Therapy Synergistically Enhances Anti-tumor Efficacy
187. Correlation Between Immune-Related Adverse Events Of Immune Checkpoint Inhibitors And The Efficacy
188. Investigation On Predictors In The Outcome Of Immune Checkpoint Inhibitors(ICIs) And Hyperprogressive Disease Triggered By ICIs
189. Investigation And Mechanism Exploration On The Association Of PRKDC Mutation And Response To Immune Checkpoint Inhibitors In Advanced Solid Tumors
190. CCND1 Amplification Contributes To Immunosuppression And The Correlation With Clinical Efficacy Of Immune Checkpoint Inhibitors In Solid Tumors
191. Identification Of Novel Immune Checkpoint Biomarkers For Survival Prediction In Lung Adenocarcinoma
192. Application Of Hyaluronic Acid Nanovesicle Delivery System In Tumor Immunotherapy
193. The Relationship Between VISTA Expression And NLR And Prognosis In Lung Cancer
194. Advances In The Treatment Of Advanced Non-small Cell Lung Cancer With Antiangiogenic Drugs Combined With Immune Checkpoint Inhibitors
195. The Effect Of Anti-PD-1 On Lung Cancer In Mice
196. Clinical Efficacy Of Immune Checkpoint Inhibitors In Elderly Patiets With Advanced Non-small Cell Lung Cancer:A Meta-analysis
197. Efficacy And Safety Of PD-1/PD-L1 Inhibitors With Chemoradiotherapy In Stage Ⅲ Non-Small Cell Lung Cancer: A Meta-Analysis
198. Research Progress And Cases Review Of Cardiaotoxicity Induced By Immune Checkpoint Inhibitors
199. Low-Dose Carboplatin Reprograms Tumor Immune Microenvironment Through STING Signaling Pathway And Synergizes With PD-1 Inhibitors In Lung Cancer
200. The Role Of PNI In Predicting The Efficacy And Prognosis Of ICIs In Patients With Advanced NSCLC
  <<First  <Prev  Next>  Last>>  Jump to